Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 28;398(10302):803-816.
doi: 10.1016/S0140-6736(21)00438-4.

Current and future status of JAK inhibitors

Donal P McLornan  1 , Janet E Pope  2 , Jason Gotlib  3 , Claire N Harrison  4
Affiliations
Review

Current and future status of JAK inhibitors

Donal P McLornan et al. Lancet. .

Abstract

An enhanced understanding of the importance of Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signalling in multiple disease states has led to an increasing applicability of therapeutic intervention with JAK inhibitors. These agents have revolutionised treatments for a heterogeneous group of disorders, such as myeloproliferative neoplasms, rheumatoid arthritis, inflammatory bowel disease, and multiple immune-driven dermatological diseases, exemplifying rapid bench-to-bedside translation. In this Therapeutics paper, we summarise the currently available data concerning the successes and safety of an array of JAK inhibitors and hypothesise on how these fields could develop.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests DPM reports speaker and advisory board fees from JAZZ pharmaceuticals and Novartis. JEP reports speaker and advisory board fees from Pfizer, Lily, AbbVie, and Gilead Pharmaceuticals. JG reports funding for clinical trial conduct, advisory boards, and travel reimbursement from Incyte; funding for clinical trial conduct, advisory board funding, and travel reimbursement from Celgene; funding for clinical trial conduct from CTI Biopharma; and funding for clinical trial conduct and advisory boards from Gilead. CNH reports speaker and advisory board fees from Novarti, Gilead, CTI Biopharma, and Celgene; speaker fees from JANNSEN; advisory board fees from AOP Pharma, Roche Pharmaceuticals, and Sierra Oncology.

MeSH terms